Nuveen
MPLT

Nuveen’s MapLight Therapeutics MPLT Stock Holding History

Nuveen’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$642K Sell
17,921
-5,168
-22% -$149K ﹤0.01% 3156
2026
Q1 		$469K Buy
23,089
+2,892
+14% +$51.7K ﹤0.01% 2862
2025
Q4 		$355K Buy
+20,197
New +$338K ﹤0.01% 2997

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen's MPLT Position: Q2 2026 in Review

Nuveen reduced its MapLight Therapeutics (MPLT) stake by 22% in Q2 2026, selling an estimated $149K and leaving 17,921 shares worth $642K. The position accounts for ﹤0.01% of the portfolio, ranked #3156.

Nuveen first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Nuveen held 17,921 shares of MapLight Therapeutics worth $642K as of Q2 2026.
  • Nuveen sold 5,168 MapLight Therapeutics shares in Q2 2026, an estimated $149K.
  • MapLight Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3156 holding.
  • Nuveen first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.